16 July 2026
16 July 2026
The trial reported that none of the 13 patients treated so far have experienced serious adverse events related to ENV-105.
The wand permits radial incisions of target tissue in all directions and can be adapted to fit patient anatomy.
The antibody uses a dual mechanism of action and works to block the interaction between TSLP and its receptor.
The purpose of the trial is to collect additional safety data supporting chronic daily dosing of SPI-1005.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
